Amgen attorneys win a megablockbuster patent case, dealing Novartis a severe setback on biosimilars play
Don’t bet against Amgen attorneys.
That’s what Umer Raffat’s old mentor Mark Schoenbaum told the Evercore ISI analyst when he was prepping for a recent deep dive on Amgen’s Enbrel.
Like other classic remarks about Amgen’s litigious nature, it was dead on.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
